Search: onr:"swepub:oai:gup.ub.gu.se/85419" >
Prognostic importan...
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial
-
- Olsson, Lars G., 1970 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
-
- Swedberg, Karl, 1944 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
-
Cleland, J. G. (author)
-
show more...
-
Spark, P. A. (author)
-
Komajda, M. (author)
-
Metra, M. (author)
-
Torp-Pedersen, C. (author)
-
Remme, W. J. (author)
-
Scherhag, A. (author)
-
Poole-Wilson, P. (author)
-
show less...
-
(creator_code:org_t)
- 2007
- 2007
- English.
-
In: Eur J Heart Fail. - 1388-9842. ; 9:8, s. 795-801
- Related links:
-
https://gup.ub.gu.se...
Abstract
Subject headings
Close
- BACKGROUND: Plasma levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP) are increased in patients with chronic heart failure (CHF). Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis. OBJECTIVES: To assess the prognostic importance of NT-pro BNP at baseline and during follow-up, in patients in whom beta-blocker therapy is initiated. METHODS: In COMET, 3029 patients with CHF in NYHA class II-IV and EF<35% were randomised to carvedilol or metoprolol tartrate and were followed for an average of 58 months. Blood samples were collected for the measurement of NT-pro BNP at baseline (n=1559) and during follow-up (n=309). RESULTS: Baseline plasma concentrations of NT-pro BNP above the median (1242 pg/ml) were associated with higher all-cause mortality (RR 2.77; 95% CI 2.33-3.3, p<0.001). Patients who achieved NT-pro BNP levels<400 pg/ml during follow-up had a lower subsequent mortality (RR 0.32; 95% CI 0.15-0.69, p=0.004). CONCLUSIONS: The plasma concentration of NT-pro BNP is a powerful predictor of mortality in patients with CHF. Patients who achieve an NT-pro BNP of <400 pg/ml subsequent to treatment with a beta-blocker have a favourable prognosis.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Adrenergic beta-Antagonists/*therapeutic use
- Aged
- Carbazoles/*therapeutic use
- Chronic Disease
- Female
- Heart Failure/*blood/drug therapy/*mortality
- Humans
- Male
- Metoprolol/*therapeutic use
- Middle Aged
- Natriuretic Peptide
- Brain/*blood
- Peptide Fragments/*blood
- Prognosis
- Propanolamines/*therapeutic use
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Olsson, Lars G., ...
-
Swedberg, Karl, ...
-
Cleland, J. G.
-
Spark, P. A.
-
Komajda, M.
-
Metra, M.
-
show more...
-
Torp-Pedersen, C ...
-
Remme, W. J.
-
Scherhag, A.
-
Poole-Wilson, P.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
Eur J Heart Fail
- By the university
-
University of Gothenburg